Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Melanoma · Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 161 (final count)
- Started
- Jan 26, 2021
- Main results expected
- Feb 3, 2026
- Fully finished
- Feb 3, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria
Measured over: Up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04609566 · record last updated 2026-07-06 · checked 2026-11-09 15:42 UTC